Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
20 participants
INTERVENTIONAL
2015-09-30
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
AIM: To determine the utility of focal LDR brachytherapy in form of hemiablative treatment for localized prostate cancer demonstrating the feasibility of the delivery of the prescription dose to the half of the prostate in terms of meeting standard dosimetric parameters while respecting same or lower tolerance doses of adjacent normal organs.
To determine acute and late rectal, urinary and sexual toxicity after this procedure.
To assess the change from baseline in QOL indicators at specific time intervals using validated international questionnaires \[International Prostate Symptom Score ( IPSS), International Index of Erectile Function ( IIEF ), Expanded Prostate Cancer Index (EPIC)\] after this treatment.
To evaluate the local tumour control in terms of biopsy outcomes after focal brachytherapy 36 months after the treatment.
To compare target coverage and relative doses to the rectum and the urethra for the same patient performing a hemigland treatment planning vs Whole gland treatment planning.
STUDY DESIGN: Multi-institution prospective trial to determine whether hemiablative treatment with LDR for prostate cancer is dosimetrically safe and feasible.This study will record data for 20 patients with ipsilateral with low and low tier intermediate risk disease.The study will record quality of life parameters in particular in terms of urinary, rectal and sexual function side effects.
INTERVENTION:
* Baseline Transperineal Template guided mapping prostate biopsy with \>20 cores (not required if already performed)
* Multiparametric MRI within the 3 months prior to registration and at 18 \& 36 months.
* Hemigland prostate region will be targeted with the prescription dose and receive 144 Gy of Iodine125 (I125).
* The quality of life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life
* Postimplant CT Planning day 30 after the implant for quality assurance.
MEASUREMENT OF ENDPOINTS :
Dosimetric parameters record, Toxicity and QOL evaluation forms, PSA follow up and biopsies at 36 months to assess local control.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prostate biopsy,Hemiablative focal Brachytherapy
This is a non-randomized, Phase II study examining the efficacy in terms of postimplant dosimetry (primary endpoint) as well as the secondary endpoints of QOL changes, toxicity, local control with post-treatment biopsy outcomes and comparison with historical whole-gland cohorts in men with early stage low volume prostate cancer treated with hemiablative focal brachytherapy
Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy
A re-staging transperineal template guided mapping prostate biopsy as currently performed at participating institutions. Hemiablative Focal brachytherapy will be performed . The affected half of the prostate will be targeted with the prescription dose and receive 145 Gy of Iodine-125 (I-125). A postimplant dosimetry will be performed 30 days after procedure. The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then 4 weeks, 6 months, 12 months, 20 months, 24 months, 32 months and 36 months after treatment. A second transperineal biopsy will be performed 36 months after the implant.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy
A re-staging transperineal template guided mapping prostate biopsy as currently performed at participating institutions. Hemiablative Focal brachytherapy will be performed . The affected half of the prostate will be targeted with the prescription dose and receive 145 Gy of Iodine-125 (I-125). A postimplant dosimetry will be performed 30 days after procedure. The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then 4 weeks, 6 months, 12 months, 20 months, 24 months, 32 months and 36 months after treatment. A second transperineal biopsy will be performed 36 months after the implant.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2\. Patients must have low or low-tier intermediate prostate cancer
* Low risk prostate cancer patients must have:
* Clinical stage ≤ T2a,
* Gleason score =6 and iPSA ≤ 10 ng/ml
* \< 25% cores positive, \< 50 % cancer in each core involved
* Low tier Intermediate risk patients may have:
* Clinical stageT2a
* Gleason score ≤ 3+4=7
* PSA ≤ 10 ng/ml
* \< 25% cores positive, \< 50 % cancer in each core
3\. Patients must be fit for general anesthetic. 4. Patients must have unilateral disease on biopsy 5. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2.
6\. Men ≥ 65 years of age with a life expectancy estimated to be \>10 years. 7. Patients must have no contraindications to interstitial prostate brachytherapy.
8\. Patients on anticoagulant therapy must be able to stop therapy safely for at least 7 days.
9\. Patients must not have any contraindications to MRI 10. IPSS \<=16
Exclusion Criteria
2. Bilateral prostatic disease
3. Prior hormonal therapy
4. Prior Transurethral resection or middle lobe resection
5. Recent IPSS\>
6. Unfit for general anesthetic
7. MRI contraindicated
8. Unable to cease anticoagulant therapy
9. Life expectancy \< 10 years
10. IPSS\>16
60 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St George Hospital, Australia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ana Fernandezots
Ana Fernandez Ots MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St George Hospital Cancer Care Centre
Kogarah, Sydney, New South Wales, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ana Fernandez, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Fernandez Ots A, Bucci J, Chin YS, Malouf D, Howie A, Enari KE. Hemiablative Focal Low Dose Rate Brachytherapy: A Phase II Trial Protocol. JMIR Res Protoc. 2016 Jun 13;5(2):e98. doi: 10.2196/resprot.5433.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STGAF
Identifier Type: -
Identifier Source: org_study_id